Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>PTEN</i> is a tumor suppressor gene that classically dampens the PI3K/AKT/mTOR growth-promoting signaling cascade.
|
31433956 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nectin-4 was overexpressed at all stages of metastasis and angiogenesis, thus appearing to play a major role in tumor relapse through the PI3K-Akt-NFκβ pathway.
|
31617074 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor suppressor phosphatase and tensin homolog deleted from chromosome 10 (PTEN) is the only known lipid phosphatase counteracting the PI3K/AKT pathway.
|
31663655 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These studies for the first time report the presence and dysfunction of LrNK cells in HCC and show that Tim-3-mediated PI3K/mTORC1 interference is responsible for the dysfunction of both tumor infiltrating cNK and LrNK cells, providing a new strategy for immune checkpoint-based targeting.
|
31848194 |
2020 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo investigation confirmed that miR-337-3p is a tumor suppressor that control expression of PIK3CA and PIK3CB encoded protein: p110α and p110β.
|
31629932 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thirty-five primary human cultures enriched in CR-CSCs, including four from chemoresistant metastatic lesions, were used for in vitro studies and to generate CR-CSC-based mouse avatars to evaluate tumor growth and progression upon treatment with BMP7v alone or in combination with standard therapy or PI3K inhibitors.
|
31591478 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibitors against PI3K, AKT and mammalian target of rapamycin (mTOR) have remarkable effects on tumor cell proliferation and radiotherapy sensitization in cell cultures and mouse models.
|
31785230 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy.
|
31832711 |
2020 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with HRR mutations had higher tumor mutation burdens (p < 0.001) and higher alterations in the PI3K-AKT-mTOR pathway (p = 0.004) than patients without these HRR mutations.
|
31603993 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Copanlisib demonstrated dose-dependent pharmacodynamic evidence of target engagement and PI3K pathway modulation/inhibition in tumor and immune cells.
|
31619463 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review we examine the role and interaction of three major cell signalling pathways, PI3K, MAPK and cAMP, in regulating tumour cell functions and discuss the prospects for exploiting this knowledge to better treat difficult to treat cancers, using glioblastoma, the most common and deadly malignant brain cancer, as the example disease.
|
30710631 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The function of hBMSC-MVs on U2OS cell progression and tumor growth was associated with PI3K/AKT and HIF-1α pathway under hypoxia.
|
30506278 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Emerging evidence suggests that genetic PI3K pathway activation can induce and/or allow cells to tolerate chromosomal instability, which-even if occurring in a low fraction of the cell population-might help to facilitate and/or drive tumour evolution.
|
31374965 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We assessed whether buparlisib, a class 1 PI3K inhibitor, can be safely combined with radiotherapy in patients with non-small cell lung carcinoma (NSCLC) and investigated its effect on tumour hypoxia.
|
30991262 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The sentence should read 'In mouse mammary tumour models, increased collagen levels and increased β1 integrin and SRC activity have been demonstrated to accompany, and promote, combined resistance to anti-human epidermal growth factor receptor 2 (HER2; also known as ERBB2) (trastuzumab and pertuzumab) and anti-PI3K (buparlisib) therapies164.'
|
30705430 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that mTOR/PI3K inhibition can produce broad spectrum tumour growth stasis in ovarian cancer xenograft models during continuous chronic treatment and this is associated with apoptosis.
|
31822716 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Highlights ALK restrains cell growth, migration and invasion in OSCC cells; miR-9 is enhanced in OSCC tissues but is repressed by ALK in OSCC cells; miR-9 inverts the repressive effect of ALK on CAL-27 and SCC-9 cells; RECK is a novel target of miR-9; ALK or RECK hinders JAK1/STAT3 and PI3K/AKT pathways in CAL-27 and SCC-9 cells; ALK prohibits tumour formation <i>in vivo</i>.
|
31349748 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this context, the inhibition of phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) and androgen receptor (AR) signaling pathways have emerged as potential therapeutic strategies against selected tumors.
|
31636720 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Autophagy-associated signaling pathways, such as the extracellular signal-regulated kinase1/2 (ERK1/2) pathway, class I phosphatidylinositol 3-phosphate kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and nuclear factor kappa-B (NF-κB) pathway, act as tumor suppressors or protect tumor cells against chemotherapy/radiotherapy-induced cytotoxicity in gliomagenesis.
|
31541887 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, we suggest that HDGF plays a substantial role in BCa and promotes tumor development and progression by regulating the PI3K-AKT signaling pathway, which provides a promising target for BCa treatment.
|
31692549 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results demonstrated that miR-605 acts as a tumor suppressor in the development of GBM by directly targeting SOX9 and inhibiting the activation of the PI3K/Akt pathway, suggesting its potential role as a therapeutic target for GBM.
|
31360068 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We further demonstrated that the combination of a PI3K/mTOR inhibitor (PF-04691502) and palbociclib completely controlled tumor growth in mice.
|
31516747 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overall, the inhibitory effect of GBEE on the growth of B16 melanoma transplant tumor in mice is related to inhibiting angiogenesis, and the mechanism involves the regulation of PI3K/Akt/ HIF-lα/VEGF signaling pathway.
|
31531063 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Profiling of somatic mutations and copy number variations (CNV) in NPC tumors identified alterations in RTK/RAS/PI3K, NOTCH, DNA repair, chromatin remodeling, cell cycle, NF-κB, and TGF-β pathways.
|
31328403 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Inactivation of the tumor suppressor phosphatase and tensin homologue deleted on Chromosome 10 (PTEN) and/or activating mutations in the proto-typical lipid kinase PI3K have emerged as some of the most frequent events associated with human cancer and as a result the PI3K pathway has become a highly sought-after target for cancer therapies.
|
30999672 |
2019 |